LivaNova PLC (LIVN) FY2026 YTD Q2 P&L / Income Statement

Revenue by Business Segment

2026-01-01 to 2026-06-30

Swipe to see the full flow
LivaNova PLC (LIVN) FY2026 YTD Q2 P&L / Income StatementIncome statement for 2026-01-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUE RECONCILIATIONREVENUEGROSSOPERATINGPRE-TAXNETCardiopulmonaryNeuromodulationNet revenueRevenue before reconciliation (calculated)OtherGross profitCost of salesOperating incomeOperating costs, including other operating expenses (calculated)Selling, general, and administrativeResearch and developmentOther operating expenseIncome (loss) before income taxOther income (expense), net (calculated)Net income (loss)Loss from equity method investmentsIncome tax (benefit) expenseIncome tax (benefit) expenseIncome tax(benefit) expense−$85.86 MRevenue before reconciliation (calculated)Revenue beforereconciliation(calculated)$748.96 MIncome (loss) before income taxIncome (loss)before income tax$45.96 MNet revenueNet revenue$752.85 MGross profitGross profit$517.42 MOperating incomeOperating income$90.96 MNet income (loss)Net income (loss)$130.86 MOperating costs, including other operating expenses (calculated)Operating costs(calculated)$426.46 MCardiopulmonaryCardiopulmonary$430.23 MOther income (expense), net (calculated)Other income,net (calculated)−$44.99 MSelling, general, and administrativeSelling, general, and administrative$301.70 MLoss from equity method investmentsLoss from equitymethod investments−$965.00 KNeuromodulationNeuromodulation$318.73 MCost of salesCost of sales$235.43 MResearch and developmentResearch and development$112.36 MOther operating expenseOther operating expense$12.41 MOtherOther$3.88 M
Chart details

LivaNova PLC (LIVN) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenue
752,845,000 US dollars
Cost of sales
235,426,000 US dollars
Gross profit
517,419,000 US dollars
Operating costs, including other operating expenses (calculated)
426,464,000 US dollars
Operating income
90,955,000 US dollars
Other income (expense), net (calculated)
negative 44,991,000 US dollars
Income (loss) before income tax
45,964,000 US dollars
Income tax (benefit) expense
negative 85,864,000 US dollars
Net income (loss)
130,863,000 US dollars
Cardiopulmonary
430,231,000 US dollars
Neuromodulation
318,733,000 US dollars
Selling, general, and administrative
301,696,000 US dollars
Research and development
112,357,000 US dollars
Other operating expense
12,411,000 US dollars
Revenue before reconciliation (calculated)
748,964,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
Other
3,881,000 US dollars. Reported reconciliation to consolidated revenue.
Loss from equity method investments
negative 965,000 US dollars. Reported below-tax contribution to net income.
Cardiopulmonary costs (calculated)
372,012,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.
Neuromodulation costs (calculated)
213,644,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.
Reconciling items (calculated)
76,234,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
  • Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
LivaNova PLC (LIVN) FY2026 YTD Q2 P&L / Income Statement Sankey chart, Business segment view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

68.7%

Gross profit / revenue

Operating margin

12.1%

Operating profit / revenue

Cash conversion

62.5%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!